{{Drugbox
| Watchedfields = changed
| verifiedrevid = 470624569
| IUPAC_name =* ''rel''-(2''R'',3''S'')-5-{[(2''R'')-3-(''tert''-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol
* (2''R''*,3''S''*)-5-{[(2''R''*)-3-(''tert''-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol
| image = Nadolol.svg
<!--Clinical data-->
| tradename = Corgard
| Drugs.com = {{drugs.com|monograph|nadolol}}
| MedlinePlus = a682666
| pregnancy_AU =  
| pregnancy_US = C
| pregnancy_category =  
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 30%
| metabolism = Nil
| elimination_half-life = 14-24 hours
| excretion = [[Kidney|Renal]] and fecal (unchanged)
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 42200-33-9
| ATC_prefix = C07
| ATC_suffix = AA12
| PubChem = 39147
| IUPHAR_ligand = 554
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01203
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 35815
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FEN504330V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00432
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 649
<!--Chemical data-->
| C=17 | H=27 | N=1 | O=4
| molecular_weight = 309.401 g/mol
| smiles = OC(CNC(C)(C)C)COc1cccc2c1C[C@H](O)[C@H](O)C2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VWPOSFSPZNDTMJ-UCWKZMIHSA-N
}}

'''Nadolol''' ('''Corgard''') is a non-selective [[beta blocker]] used in the treatment of [[hypertension|high blood pressure]] and [[angina pectoris|chest pain]].  Additionally, it is often prescribed in the treatment of [[atrial fibrillation]], [[Migraine|migraine headaches]], and complications of [[cirrhosis]].

==Chemistry==
Nadolol is a mixture of [[stereoisomer]]s. It is [[Chemical polarity|polar]] and [[Hydrophile|hydrophilic]], with low [[lipid]] solubility.<ref>{{cite journal | vauthors = Bragg W ''et al'' | date = Nov 2008 | title = Optimized separation of beta-blockers with multiple chiral centers using capillary electrochromatography-mass spectrometry | journal = J Chromatogr B Analyt Technol Biomed Life Sci. | volume = 875 | issue = 1| pages = 304–16 | doi = 10.1016/j.jchromb.2008.06.028 | pmid = 18619928 | pmc=2680439}}</ref>
[[File:Nadolol Structural Formulae.svg|thumb|right|Four stereoisomers of nadolol]]

==Medical uses==

Nadolol is used to treat [[hypertension]] and for long-term treatment of [[angina pectoris]] and is approved by the FDA for these purposes.<ref name=AccessMedNadolol>Nadolol entry in AccessMedicine. McGraw-Hill Global Education Holdings, LLC. Accessed November 8, 2014</ref>

It is regularly used off-label<ref name=AccessMedNadolol/> for control of heart rate in people with [[atrial fibrillation]],<ref>{{cite journal | pmid = 24682347 | doi=10.1161/CIR.0000000000000041 | pmc=4676081 | volume=130 | title=2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society | journal=Circulation | pages=e199-267 | vauthors=January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW}}</ref> prevention of migraine headaches;<ref>{{cite journal | pmid = 22529202 | doi=10.1212/WNL.0b013e3182535d20 | volume=78 | issue=17 | title=Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society | pmc=3335452 | year=2012 | journal=Neurology | pages=1337–45 | vauthors=Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E}}</ref> prevention of bleeding veins in people with [[portal hypertension]] caused by [[cirrhosis]];<ref>{{cite journal | pmid = 24714633 | volume=27 | issue=1 | title=Beta-blockers in liver cirrhosis | pmc=3959530 | journal=Ann Gastroenterol | pages=20–26 | vauthors=Giannelli V, Lattanzi B, Thalheimer U, Merli M}}</ref> and to treat people with high levels of [[thyroid hormone]].<ref>{{cite journal | vauthors = Bahn RS ''et al'' | year = 2011 | title = Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists | url = | journal = Thyroid | volume = 21 | issue = 6| pages = 593–646 | pmid = 21510801 | doi=10.1089/thy.2010.0417}}</ref>

Nadolol is one of the preferred [[beta-blockers]] in the management of patients with [[long QT syndrome|LQTS]] for shortening of the QT interval and prevention of [[ventricular arrhythmia]]. It is more efficacious than [[metoprolol]] in the prevention of breakthrough cardiac events while on therapy and is equivalent to [[propranolol]].<ref>{{cite journal|vauthors=Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, Hauer RN, Beckmann BM, Spazzolini C, Rordorf R, Rydberg A, Clur SA, Fischer M, van den Heuvel F, Kääb S, Blom NA, Ackerman MJ, Schwartz PJ, Wilde AA |title=Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol|journal=Journal of the American College of Cardiology|date=Nov 13, 2012|volume=60|issue=20|pages=2092–9|pmid=23083782|doi=10.1016/j.jacc.2012.07.046|pmc=3515779}}</ref> Nadolol has the advantage of once daily dosing and thus improved patient compliance. For patients with decreased kidney function, nadolol may be dosed less often.<ref>{{cite web|url=http://reference.medscape.com/drug/corgard-nadolol-342361|title=Corgard (nadolol) dosing, indications, interactions, adverse effects, and more|website=reference.medscape.com|accessdate=27 May 2017}}</ref> It has also been found to be useful ([[off-label]]) for several [[neurological disorder]]s such as the prevention of [[migraine]] attacks,<ref>{{cite web|url=http://patient.info/medicine/nadolol-a-beta-blocker-corgard|title=Nadolol - a beta-blocker - Corgard. High blood pressure drugs|website=patient.info|accessdate=27 May 2017}}</ref> [[attention deficit/hyperactivity disorder]](ADHD)<ref>{{cite web|url=https://books.google.com/books?id=EkyTTvjNRZAC&pg=PA669&lpg=PA669&dq=Nadolol+for+ADHD&source=bl&ots=AHBVTAhCwv&sig=w0nW8Plyub3GN87J7itGz1fB11Y&hl=en&sa=X&ei=UAjRVMWkJoatyQSDzoDQCA&ved=0CFEQ6AEwBTgK#v=onepage&q=Nadolol+for+ADHD&f=false|title=Attention-deficit Hyperactivity Disorder: A Clinical Workbook|first1=Russell A.|last1=Barkley|first2=Kevin R.|last2=Murphy|date=27 May 2017|publisher=Guilford Press|accessdate=27 May 2017|via=Google Books}}</ref> and its use has been explored as a treatment for [[essential tremor]]<ref>{{cite journal | vauthors = Zesiewicz TA ''et al'' | date = Nov 2011 | title = Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology | journal = Neurology | volume = 77 | issue = 19| pages = 1752–5 | doi = 10.1212/WNL.0b013e318236f0fd | pmid = 22013182 | pmc=3208950}}</ref> and [[Parkinson's disease]]<ref name=MedlinePlus>U.S. National Library of Medicine [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682666.html Nadolol entry in Medline Plus]</ref> but neither is well established.<ref>{{cite journal | doi = 10.1002/ana.410160412 | title = Peripheral beta-adrenergic blockade treatment of parkinsonian tremor | pages= 505–508 |volume=16|date=October 1984|journal=Ann Neurol.}}</ref><ref>{{cite web|url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682666.html|title=Nadolol: MedlinePlus Drug Information|website=www.nlm.nih.gov|accessdate=27 May 2017}}</ref><ref>{{cite web|url=http://www.drugs.com/dosage/nadolol.html|title=Nadolol Dosage Guide with Precautions - Drugs.com|website=drugs.com|accessdate=27 May 2017}}</ref>

==Mechanism of action==
{{Main|Beta-blocker}}

Nadolol is a non-selective [[beta blocker]]; that is, it non-selectively blocks both [[beta-1 receptor|beta-1]] and [[beta-2 receptor]]s. It has a preference for beta-1 receptors, which are predominantly located in the [[heart]], thereby inhibiting the effects of [[catecholamine]]s and causing a decrease in [[heart rate]] and [[blood pressure]]. Its inhibition of beta-2 receptors, which are mainly located in the [[bronchus|bronchial]] [[smooth muscle]] of the [[airway]]s, leads to airway constriction similar to that seen in [[asthma]]. Inhibition of beta-1 receptors in the [[juxtaglomerular apparatus]] of the [[kidney]] inhibits the [[renin-angiotensin system]], causing a decrease in [[vasoconstriction]] and a decrease in water retention. Nadolol's inhibition of beta-1 receptors in the heart and kidney leads to its effects on lowering blood pressure.

The drug impairs [[atrioventricular node|AV node]] conduction and decreases [[sinoatrial node|sinus]] rate.

Nadolol may also increase [[blood plasma|plasma]] [[triglyceride]]s and decrease [[High density lipoprotein|HDL]]-[[cholesterol]] levels. {{Citation needed|date=January 2017}}

==Side effects==
The most common side effects include dizziness and fatigue.<ref name=MedlinePlus/>

==Contraindications==
Nadolol and other beta blockers should be used with cautions in people with [[heart failure]] and its use should not be abruptly stopped.  It is contraindicated for people with asthma, a [[bradycardia|slow heart rate]] and certain severe heart problems.<ref name=Label>{{cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018063s060lbl.pdf|title=Corgard Label|website=fda.gov|accessdate=27 May 2017}}</ref>

==See also==
* [[Renin-angiotensin system]]
* [[Anti-hypertensive]]
* [[Cardiology]]

==References==
{{Reflist|35em}}

{{Endothelial antihypertensives}}
{{Adrenergics}}

[[Category:Beta blockers]]
[[Category:Phenol ethers]]
[[Category:Alcohols]]
[[Category:Tetralins]]
[[Category:Peripherally selective drugs]]